Global Inflammatory Bowel Disease Therapy Market Growth (Status and Outlook) 2024-2030

2024

Global Inflammatory Bowel Disease Therapy Market Growth (Status and Outlook) 2024-2030

Name: Global Inflammatory Bowel Disease Therapy Market Growth (Status and Outlook) 2024-2030
Brand: Bonafide Research
SKU: 95001203
Price: 3450 USD
Availability: InStock
Rating: 5 (14.65 reviews)

Inflammatory Bowel Disease Therapy market size was valued at US$ 16.90 billion in 2024, driven by advancements in drug therapies and diagnostics for chronic digestive diseases.

Bonafide Trust
20-09-2024
Pages : 87
Figures : 79
Tables : 96
Region : Global
Category : Lifescience & Healthcare
Pharmaceutical

Schedule a Call

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

The global inflammatory bowel disease (IBD) therapy market has witnessed significant growth due to the rising prevalence of IBD worldwide, coupled with increasing awareness about the condition and advancements in treatment options. IBD, which includes diseases like Crohn's disease and ulcerative colitis, causes chronic inflammation in the digestive tract and leads to symptoms such as abdominal pain, diarrhea, and fatigue. The global rise in IBD cases is primarily driven by environmental factors, urbanization, and lifestyle changes, including dietary habits and smoking. Furthermore, the prevalence of IBD is increasing in both developed and developing countries, with more people being diagnosed at younger ages. This rise in the number of affected individuals is fueling the demand for effective therapies to manage the disease and improve patients’ quality of life. The market for IBD therapies is diverse, with treatments ranging from conventional drugs, such as corticosteroids and immunosuppressants, to biologic therapies. Over the past decade, biologics have revolutionized the treatment of IBD, as they specifically target the inflammatory pathways that drive the disease. This shift towards more targeted treatments has significantly improved patient outcomes and reduced flare-ups, leading to better disease management. Moreover, the growing number of treatment options, coupled with the increasing healthcare expenditure and advancements in drug delivery systems, is expected to further propel the market for IBD therapies. With ongoing research and innovations in the development of personalized therapies, the IBD therapy market is expected to continue expanding, offering better management strategies for individuals affected by this chronic condition.

According to Publisher, the global Inflammatory Bowel Disease Therapy market size was valued at US$ 16900 million in 2024. With growing demand in downstream market, the Inflammatory Bowel Disease Therapy is forecast to a readjusted size of US$ 21830 million by 2030 with a CAGR of 3.7% during review period. In addition to the rising prevalence of IBD, the growing awareness about early diagnosis and treatment options is further contributing to the growth of the IBD therapy market. Healthcare providers are increasingly focusing on early intervention, which helps to manage symptoms and prevent long-term complications. Furthermore, lifestyle modifications, such as smoking cessation, stress management, and changes in diet, play a crucial role in managing IBD and reducing disease progression. The expansion of healthcare coverage and access to medical services in both developed and emerging markets has also boosted the availability of treatments, ensuring that patients can access a variety of therapeutic options. One of the key drivers of market growth is the increasing adoption of biologics, which target specific inflammatory mediators involved in IBD. Biologic treatments, such as tumor necrosis factor (TNF) inhibitors, interleukin inhibitors, and monoclonal antibodies, have demonstrated superior efficacy in controlling inflammation, reducing flare-ups, and improving remission rates in patients with moderate to severe IBD. These treatments are particularly beneficial for patients who do not respond well to conventional therapies, offering them a chance at better disease management and a higher quality of life. Alongside biologics, immunosuppressants and corticosteroids continue to play a significant role in managing IBD. Immunosuppressants help regulate the immune system, while corticosteroids offer rapid relief during acute flare-ups. As the market continues to evolve, the development of combination therapies, which combine biologics with immunosuppressants or corticosteroids, is expected to further enhance treatment outcomes. Additionally, the rise in precision medicine, where treatments are tailored to an individual’s genetic and molecular profile, is improving the effectiveness of IBD management. With these advancements, the IBD therapy market is set to expand further, offering more personalized and effective treatment options for patients worldwide.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample

The IBD therapy market is segmented by type, with the major categories being biologic therapy, immunosuppressive therapy, corticosteroids, and other drug therapies. Biologic therapy is the leading segment in the IBD market, as biologics have revolutionized the treatment landscape for conditions like Crohn's disease and ulcerative colitis. Biologics include drugs like tumor necrosis factor (TNF) inhibitors, interleukin inhibitors, and monoclonal antibodies, which target specific immune cells and inflammatory pathways involved in IBD. These therapies have shown great promise in reducing inflammation, preventing flare-ups, and maintaining remission, particularly for patients with moderate to severe disease. Due to their targeted action and ability to provide long-term relief, biologics are becoming increasingly popular, leading to their growing share of the market. The use of biologics has also led to improvements in patients' overall quality of life, making them the preferred option for many healthcare providers. Another significant segment in the IBD therapy market is immunosuppressive therapy, which includes drugs such as thiopurines, methotrexate, and cyclosporine. These therapies work by suppressing the immune system to reduce inflammation and prevent tissue damage. Immunosuppressive drugs are often used in combination with biologics to enhance their effectiveness or for patients who cannot afford biologics. Corticosteroids, although effective in managing acute flare-ups, are limited in long-term use due to potential side effects. However, they remain a critical part of the treatment regimen for IBD patients, especially during active disease phases. Other drug therapies, such as antibiotics, anti-diarrheals, and pain relievers, are used to manage symptoms and improve the overall well-being of patients but do not directly address the underlying inflammation. The growing development of biologic therapies and the increasing use of biosimilars are expected to continue driving growth in this segment, as they offer more effective and targeted treatment options.

The IBD therapy market is further segmented based on patient demographics and healthcare settings. The market is primarily divided into adult and pediatric patient segments, with the adult segment holding the largest share due to the higher incidence of IBD in adults. Crohn’s disease and ulcerative colitis are more commonly diagnosed in individuals between the ages of 20 and 40, particularly in developed countries where lifestyle factors and environmental influences contribute to the disease's onset. Biologics and immunosuppressants are the preferred treatment options for adult patients, particularly those with moderate to severe disease. As the prevalence of IBD continues to rise in adult populations, the demand for these therapies is expected to grow, driving the expansion of the IBD therapy market. The pediatric segment, though smaller, is gaining attention as IBD diagnoses in children and adolescents are on the rise. Pediatric patients often experience more aggressive disease progression, which requires careful treatment management. For these patients, biologic therapies are becoming increasingly important as they provide more effective long-term disease control compared to traditional therapies. The challenge in treating pediatric IBD lies in adjusting doses to accommodate the child's size and managing the potential side effects of long-term therapy. The healthcare settings for IBD treatment include hospitals, outpatient clinics, and home care. Hospitals and outpatient clinics are key venues for the administration of biologic drugs, immunosuppressive therapies, and corticosteroids. Hospital settings are essential for managing severe cases of IBD, where patients require more intensive monitoring and specialized care. However, as the demand for biologics and immunosuppressive therapies increases, home care is becoming a more viable option, especially for patients who are stable and do not require hospitalization. Home care services, such as home infusion therapies for biologics, are becoming more popular, allowing patients to receive treatments in the comfort of their homes while reducing healthcare costs. This shift towards home-based care is expected to drive growth in the IBD therapy market as patients seek more convenient and cost-effective treatment options.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Research Analyst

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Inflammatory Bowel Disease Therapy Market Size 2019-2030
2.1.2 Inflammatory Bowel Disease Therapy Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Inflammatory Bowel Disease Therapy Segment by Type
2.2.1 Ulcerative Colitis
2.2.2 Crohns Disease
2.2.3 Others
2.3 Inflammatory Bowel Disease Therapy Market Size by Type
2.3.1 Inflammatory Bowel Disease Therapy Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Inflammatory Bowel Disease Therapy Market Size Market Share by Type (2019-2024)
2.4 Inflammatory Bowel Disease Therapy Segment by Application
2.4.1 Hospital
2.4.2 Medical Research Organization
2.4.3 Other
2.5 Inflammatory Bowel Disease Therapy Market Size by Application
2.5.1 Inflammatory Bowel Disease Therapy Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Inflammatory Bowel Disease Therapy Market Size Market Share by Application (2019-2024)
3 Inflammatory Bowel Disease Therapy Market Size by Player
3.1 Inflammatory Bowel Disease Therapy Market Size Market Share by Players
3.1.1 Global Inflammatory Bowel Disease Therapy Revenue by Players (2019-2024)
3.1.2 Global Inflammatory Bowel Disease Therapy Revenue Market Share by Players (2019-2024)
3.2 Global Inflammatory Bowel Disease Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Inflammatory Bowel Disease Therapy by Regions
4.1 Inflammatory Bowel Disease Therapy Market Size by Regions (2019-2024)
4.2 Americas Inflammatory Bowel Disease Therapy Market Size Growth (2019-2024)
4.3 APAC Inflammatory Bowel Disease Therapy Market Size Growth (2019-2024)
4.4 Europe Inflammatory Bowel Disease Therapy Market Size Growth (2019-2024)
4.5 Middle East & Africa Inflammatory Bowel Disease Therapy Market Size Growth (2019-2024)
5 Americas
5.1 Americas Inflammatory Bowel Disease Therapy Market Size by Country (2019-2024)
5.2 Americas Inflammatory Bowel Disease Therapy Market Size by Type (2019-2024)
5.3 Americas Inflammatory Bowel Disease Therapy Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Inflammatory Bowel Disease Therapy Market Size by Region (2019-2024)
6.2 APAC Inflammatory Bowel Disease Therapy Market Size by Type (2019-2024)
6.3 APAC Inflammatory Bowel Disease Therapy Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Inflammatory Bowel Disease Therapy by Country (2019-2024)
7.2 Europe Inflammatory Bowel Disease Therapy Market Size by Type (2019-2024)
7.3 Europe Inflammatory Bowel Disease Therapy Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Inflammatory Bowel Disease Therapy by Region (2019-2024)
8.2 Middle East & Africa Inflammatory Bowel Disease Therapy Market Size by Type (2019-2024)
8.3 Middle East & Africa Inflammatory Bowel Disease Therapy Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Inflammatory Bowel Disease Therapy Market Forecast
10.1 Global Inflammatory Bowel Disease Therapy Forecast by Regions (2025-2030)
10.1.1 Global Inflammatory Bowel Disease Therapy Forecast by Regions (2025-2030)
10.1.2 Americas Inflammatory Bowel Disease Therapy Forecast
10.1.3 APAC Inflammatory Bowel Disease Therapy Forecast
10.1.4 Europe Inflammatory Bowel Disease Therapy Forecast
10.1.5 Middle East & Africa Inflammatory Bowel Disease Therapy Forecast
10.2 Americas Inflammatory Bowel Disease Therapy Forecast by Country (2025-2030)
10.2.1 United States Inflammatory Bowel Disease Therapy Market Forecast
10.2.2 Canada Inflammatory Bowel Disease Therapy Market Forecast
10.2.3 Mexico Inflammatory Bowel Disease Therapy Market Forecast
10.2.4 Brazil Inflammatory Bowel Disease Therapy Market Forecast
10.3 APAC Inflammatory Bowel Disease Therapy Forecast by Region (2025-2030)
10.3.1 China Inflammatory Bowel Disease Therapy Market Forecast
10.3.2 Japan Inflammatory Bowel Disease Therapy Market Forecast
10.3.3 Korea Inflammatory Bowel Disease Therapy Market Forecast
10.3.4 Southeast Asia Inflammatory Bowel Disease Therapy Market Forecast
10.3.5 India Inflammatory Bowel Disease Therapy Market Forecast
10.3.6 Australia Inflammatory Bowel Disease Therapy Market Forecast
10.4 Europe Inflammatory Bowel Disease Therapy Forecast by Country (2025-2030)
10.4.1 Germany Inflammatory Bowel Disease Therapy Market Forecast
10.4.2 France Inflammatory Bowel Disease Therapy Market Forecast
10.4.3 UK Inflammatory Bowel Disease Therapy Market Forecast
10.4.4 Italy Inflammatory Bowel Disease Therapy Market Forecast
10.4.5 Russia Inflammatory Bowel Disease Therapy Market Forecast
10.5 Middle East & Africa Inflammatory Bowel Disease Therapy Forecast by Region (2025-2030)
10.5.1 Egypt Inflammatory Bowel Disease Therapy Market Forecast
10.5.2 South Africa Inflammatory Bowel Disease Therapy Market Forecast
10.5.3 Israel Inflammatory Bowel Disease Therapy Market Forecast
10.5.4 Turkey Inflammatory Bowel Disease Therapy Market Forecast
10.5.5 GCC Countries Inflammatory Bowel Disease Therapy Market Forecast
10.6 Global Inflammatory Bowel Disease Therapy Forecast by Type (2025-2030)
10.7 Global Inflammatory Bowel Disease Therapy Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Information
11.1.2 Johnson & Johnson Inflammatory Bowel Disease Therapy Product Offered
11.1.3 Johnson & Johnson Inflammatory Bowel Disease Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Johnson & Johnson Main Business Overview
11.1.5 Johnson & Johnson Latest Developments
11.2 AbbVie
11.2.1 AbbVie Company Information
11.2.2 AbbVie Inflammatory Bowel Disease Therapy Product Offered
11.2.3 AbbVie Inflammatory Bowel Disease Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 AbbVie Main Business Overview
11.2.5 AbbVie Latest Developments
11.3 Takeda Pharmaceutical Company
11.3.1 Takeda Pharmaceutical Company Company Information
11.3.2 Takeda Pharmaceutical Company Inflammatory Bowel Disease Therapy Product Offered
11.3.3 Takeda Pharmaceutical Company Inflammatory Bowel Disease Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Takeda Pharmaceutical Company Main Business Overview
11.3.5 Takeda Pharmaceutical Company Latest Developments
11.4 Abbott
11.4.1 Abbott Company Information
11.4.2 Abbott Inflammatory Bowel Disease Therapy Product Offered
11.4.3 Abbott Inflammatory Bowel Disease Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Abbott Main Business Overview
11.4.5 Abbott Latest Developments
11.5 Celgene Corporation
11.5.1 Celgene Corporation Company Information
11.5.2 Celgene Corporation Inflammatory Bowel Disease Therapy Product Offered
11.5.3 Celgene Corporation Inflammatory Bowel Disease Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Celgene Corporation Main Business Overview
11.5.5 Celgene Corporation Latest Developments
11.6 Innovate Biopharma
11.6.1 Innovate Biopharma Company Information
11.6.2 Innovate Biopharma Inflammatory Bowel Disease Therapy Product Offered
11.6.3 Innovate Biopharma Inflammatory Bowel Disease Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Innovate Biopharma Main Business Overview
11.6.5 Innovate Biopharma Latest Developments
11.7 Cosmo Pharmaceuticals
11.7.1 Cosmo Pharmaceuticals Company Information
11.7.2 Cosmo Pharmaceuticals Inflammatory Bowel Disease Therapy Product Offered
11.7.3 Cosmo Pharmaceuticals Inflammatory Bowel Disease Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Cosmo Pharmaceuticals Main Business Overview
11.7.5 Cosmo Pharmaceuticals Latest Developments
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Information
11.8.2 Gilead Sciences Inflammatory Bowel Disease Therapy Product Offered
11.8.3 Gilead Sciences Inflammatory Bowel Disease Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Gilead Sciences Main Business Overview
11.8.5 Gilead Sciences Latest Developments
11.9 Pfizer
11.9.1 Pfizer Company Information
11.9.2 Pfizer Inflammatory Bowel Disease Therapy Product Offered
11.9.3 Pfizer Inflammatory Bowel Disease Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Pfizer Main Business Overview
11.9.5 Pfizer Latest Developments
12 Research Findings and Conclusion

Table 1. Inflammatory Bowel Disease Therapy Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Ulcerative Colitis
Table 3. Major Players of Crohns Disease
Table 4. Major Players of Others
Table 5. Inflammatory Bowel Disease Therapy Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 6. Global Inflammatory Bowel Disease Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 7. Global Inflammatory Bowel Disease Therapy Market Size Market Share by Type (2019-2024)
Table 8. Inflammatory Bowel Disease Therapy Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 9. Global Inflammatory Bowel Disease Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 10. Global Inflammatory Bowel Disease Therapy Market Size Market Share by Application (2019-2024)
Table 11. Global Inflammatory Bowel Disease Therapy Revenue by Players (2019-2024) & ($ Millions)
Table 12. Global Inflammatory Bowel Disease Therapy Revenue Market Share by Player (2019-2024)
Table 13. Inflammatory Bowel Disease Therapy Key Players Head office and Products Offered
Table 14. Inflammatory Bowel Disease Therapy Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Inflammatory Bowel Disease Therapy Market Size by Regions 2019-2024 & ($ Millions)
Table 18. Global Inflammatory Bowel Disease Therapy Market Size Market Share by Regions (2019-2024)
Table 19. Global Inflammatory Bowel Disease Therapy Revenue by Country/Region (2019-2024) & ($ millions)
Table 20. Global Inflammatory Bowel Disease Therapy Revenue Market Share by Country/Region (2019-2024)
Table 21. Americas Inflammatory Bowel Disease Therapy Market Size by Country (2019-2024) & ($ Millions)
Table 22. Americas Inflammatory Bowel Disease Therapy Market Size Market Share by Country (2019-2024)
Table 23. Americas Inflammatory Bowel Disease Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 24. Americas Inflammatory Bowel Disease Therapy Market Size Market Share by Type (2019-2024)
Table 25. Americas Inflammatory Bowel Disease Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 26. Americas Inflammatory Bowel Disease Therapy Market Size Market Share by Application (2019-2024)
Table 27. APAC Inflammatory Bowel Disease Therapy Market Size by Region (2019-2024) & ($ Millions)
Table 28. APAC Inflammatory Bowel Disease Therapy Market Size Market Share by Region (2019-2024)
Table 29. APAC Inflammatory Bowel Disease Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 30. APAC Inflammatory Bowel Disease Therapy Market Size Market Share by Type (2019-2024)
Table 31. APAC Inflammatory Bowel Disease Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 32. APAC Inflammatory Bowel Disease Therapy Market Size Market Share by Application (2019-2024)
Table 33. Europe Inflammatory Bowel Disease Therapy Market Size by Country (2019-2024) & ($ Millions)
Table 34. Europe Inflammatory Bowel Disease Therapy Market Size Market Share by Country (2019-2024)
Table 35. Europe Inflammatory Bowel Disease Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 36. Europe Inflammatory Bowel Disease Therapy Market Size Market Share by Type (2019-2024)
Table 37. Europe Inflammatory Bowel Disease Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 38. Europe Inflammatory Bowel Disease Therapy Market Size Market Share by Application (2019-2024)
Table 39. Middle East & Africa Inflammatory Bowel Disease Therapy Market Size by Region (2019-2024) & ($ Millions)
Table 40. Middle East & Africa Inflammatory Bowel Disease Therapy Market Size Market Share by Region (2019-2024)
Table 41. Middle East & Africa Inflammatory Bowel Disease Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 42. Middle East & Africa Inflammatory Bowel Disease Therapy Market Size Market Share by Type (2019-2024)
Table 43. Middle East & Africa Inflammatory Bowel Disease Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 44. Middle East & Africa Inflammatory Bowel Disease Therapy Market Size Market Share by Application (2019-2024)
Table 45. Key Market Drivers & Growth Opportunities of Inflammatory Bowel Disease Therapy
Table 46. Key Market Challenges & Risks of Inflammatory Bowel Disease Therapy
Table 47. Key Industry Trends of Inflammatory Bowel Disease Therapy
Table 48. Global Inflammatory Bowel Disease Therapy Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 49. Global Inflammatory Bowel Disease Therapy Market Size Market Share Forecast by Regions (2025-2030)
Table 50. Global Inflammatory Bowel Disease Therapy Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 51. Global Inflammatory Bowel Disease Therapy Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 52. Johnson & Johnson Details, Company Type, Inflammatory Bowel Disease Therapy Area Served and Its Competitors
Table 53. Johnson & Johnson Inflammatory Bowel Disease Therapy Product Offered
Table 54. Johnson & Johnson Inflammatory Bowel Disease Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 55. Johnson & Johnson Main Business
Table 56. Johnson & Johnson Latest Developments
Table 57. AbbVie Details, Company Type, Inflammatory Bowel Disease Therapy Area Served and Its Competitors
Table 58. AbbVie Inflammatory Bowel Disease Therapy Product Offered
Table 59. AbbVie Main Business
Table 60. AbbVie Inflammatory Bowel Disease Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 61. AbbVie Latest Developments
Table 62. Takeda Pharmaceutical Company Details, Company Type, Inflammatory Bowel Disease Therapy Area Served and Its Competitors
Table 63. Takeda Pharmaceutical Company Inflammatory Bowel Disease Therapy Product Offered
Table 64. Takeda Pharmaceutical Company Main Business
Table 65. Takeda Pharmaceutical Company Inflammatory Bowel Disease Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 66. Takeda Pharmaceutical Company Latest Developments
Table 67. Abbott Details, Company Type, Inflammatory Bowel Disease Therapy Area Served and Its Competitors
Table 68. Abbott Inflammatory Bowel Disease Therapy Product Offered
Table 69. Abbott Main Business
Table 70. Abbott Inflammatory Bowel Disease Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 71. Abbott Latest Developments
Table 72. Celgene Corporation Details, Company Type, Inflammatory Bowel Disease Therapy Area Served and Its Competitors
Table 73. Celgene Corporation Inflammatory Bowel Disease Therapy Product Offered
Table 74. Celgene Corporation Main Business
Table 75. Celgene Corporation Inflammatory Bowel Disease Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 76. Celgene Corporation Latest Developments
Table 77. Innovate Biopharma Details, Company Type, Inflammatory Bowel Disease Therapy Area Served and Its Competitors
Table 78. Innovate Biopharma Inflammatory Bowel Disease Therapy Product Offered
Table 79. Innovate Biopharma Main Business
Table 80. Innovate Biopharma Inflammatory Bowel Disease Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 81. Innovate Biopharma Latest Developments
Table 82. Cosmo Pharmaceuticals Details, Company Type, Inflammatory Bowel Disease Therapy Area Served and Its Competitors
Table 83. Cosmo Pharmaceuticals Inflammatory Bowel Disease Therapy Product Offered
Table 84. Cosmo Pharmaceuticals Main Business
Table 85. Cosmo Pharmaceuticals Inflammatory Bowel Disease Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 86. Cosmo Pharmaceuticals Latest Developments
Table 87. Gilead Sciences Details, Company Type, Inflammatory Bowel Disease Therapy Area Served and Its Competitors
Table 88. Gilead Sciences Inflammatory Bowel Disease Therapy Product Offered
Table 89. Gilead Sciences Main Business
Table 90. Gilead Sciences Inflammatory Bowel Disease Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 91. Gilead Sciences Latest Developments
Table 92. Pfizer Details, Company Type, Inflammatory Bowel Disease Therapy Area Served and Its Competitors
Table 93. Pfizer Inflammatory Bowel Disease Therapy Product Offered
Table 94. Pfizer Main Business
Table 95. Pfizer Inflammatory Bowel Disease Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 96. Pfizer Latest Developments
List of

Figure 1. Inflammatory Bowel Disease Therapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Inflammatory Bowel Disease Therapy Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Inflammatory Bowel Disease Therapy Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Inflammatory Bowel Disease Therapy Sales Market Share by Country/Region (2023)
Figure 8. Inflammatory Bowel Disease Therapy Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Inflammatory Bowel Disease Therapy Market Size Market Share by Type in 2023
Figure 10. Inflammatory Bowel Disease Therapy in Hospital
Figure 11. Global Inflammatory Bowel Disease Therapy Market: Hospital (2019-2024) & ($ Millions)
Figure 12. Inflammatory Bowel Disease Therapy in Medical Research Organization
Figure 13. Global Inflammatory Bowel Disease Therapy Market: Medical Research Organization (2019-2024) & ($ Millions)
Figure 14. Inflammatory Bowel Disease Therapy in Other
Figure 15. Global Inflammatory Bowel Disease Therapy Market: Other (2019-2024) & ($ Millions)
Figure 16. Global Inflammatory Bowel Disease Therapy Market Size Market Share by Application in 2023
Figure 17. Global Inflammatory Bowel Disease Therapy Revenue Market Share by Player in 2023
Figure 18. Global Inflammatory Bowel Disease Therapy Market Size Market Share by Regions (2019-2024)
Figure 19. Americas Inflammatory Bowel Disease Therapy Market Size 2019-2024 ($ Millions)
Figure 20. APAC Inflammatory Bowel Disease Therapy Market Size 2019-2024 ($ Millions)
Figure 21. Europe Inflammatory Bowel Disease Therapy Market Size 2019-2024 ($ Millions)
Figure 22. Middle East & Africa Inflammatory Bowel Disease Therapy Market Size 2019-2024 ($ Millions)
Figure 23. Americas Inflammatory Bowel Disease Therapy Value Market Share by Country in 2023
Figure 24. United States Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 25. Canada Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 26. Mexico Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 27. Brazil Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 28. APAC Inflammatory Bowel Disease Therapy Market Size Market Share by Region in 2023
Figure 29. APAC Inflammatory Bowel Disease Therapy Market Size Market Share by Type in 2023
Figure 30. APAC Inflammatory Bowel Disease Therapy Market Size Market Share by Application in 2023
Figure 31. China Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 32. Japan Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 33. Korea Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 34. Southeast Asia Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 35. India Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 36. Australia Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 37. Europe Inflammatory Bowel Disease Therapy Market Size Market Share by Country in 2023
Figure 38. Europe Inflammatory Bowel Disease Therapy Market Size Market Share by Type (2019-2024)
Figure 39. Europe Inflammatory Bowel Disease Therapy Market Size Market Share by Application (2019-2024)
Figure 40. Germany Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 41. France Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 42. UK Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 43. Italy Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 44. Russia Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 45. Middle East & Africa Inflammatory Bowel Disease Therapy Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa Inflammatory Bowel Disease Therapy Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa Inflammatory Bowel Disease Therapy Market Size Market Share by Application (2019-2024)
Figure 48. Egypt Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 49. South Africa Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 50. Israel Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 51. Turkey Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 52. GCC Country Inflammatory Bowel Disease Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 53. Americas Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 54. APAC Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 55. Europe Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 56. Middle East & Africa Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 57. United States Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 58. Canada Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 59. Mexico Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 60. Brazil Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 61. China Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 62. Japan Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 63. Korea Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 64. Southeast Asia Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 65. India Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 66. Australia Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 67. Germany Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 68. France Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 69. UK Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 70. Italy Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 71. Russia Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 72. Spain Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 73. Egypt Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 74. South Africa Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 75. Israel Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 76. Turkey Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 77. GCC Countries Inflammatory Bowel Disease Therapy Market Size 2025-2030 ($ Millions)
Figure 78. Global Inflammatory Bowel Disease Therapy Market Size Market Share Forecast by Type (2025-2030)
Figure 79. Global Inflammatory Bowel Disease Therapy Market Size Market Share Forecast by Application (2025-2030)

Related Reports

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted